91. Nat Commun. 2018 Mar 9;9(1):1024. doi: 10.1038/s41467-018-03264-2.MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducinga stem cell-like state.Poli V(1)(2), Fagnocchi L(1)(2)(3), Fasciani A(1)(2), Cherubini A(2), MazzoleniS(2), Ferrillo S(2), Miluzio A(2), Gaudioso G(2)(4), Vaira V(2)(4), Turdo A(5),Giaggianesi M(5), Chinnici A(5), Lipari E(5), Bicciato S(6), Bosari S(4), Todaro M(7), Zippo A(8)(9)(10).Author information: (1)Laboratory of Chromatin Biology & Epigenetics, Center for Integrative Biology (CIBIO), University of Trento, 38123, Trento, Italy.(2)Fondazione Istituto Nazionale di Genetica Molecolare "Romeo ed EnricaInvernizzi", Via F. Sforza 35, 20122, Milan, Italy.(3)Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale MaggiorePoliclinico, Milan, 20122, Italy.(4)Department of Pathophysiology and Transplantation, University of Milan, Milan,20122, Italy.(5)Dipartimento di Biotecnologie Mediche e Medicina Legale Sezione di Biochimica Medica, Facoltà di Medicina e Chirurgia, Policlinico "P.Giaccone", Università di Palermo, Palermo, 90127, Italy.(6)Center for Genome Research, University of Modena and Reggio Emilia, Modena,41125, Italy.(7)DiBiMIS, University of Palermo, Palermo, 90127, Italy.(8)Laboratory of Chromatin Biology & Epigenetics, Center for Integrative Biology (CIBIO), University of Trento, 38123, Trento, Italy. alessio.zippo@unitn.it.(9)Fondazione Istituto Nazionale di Genetica Molecolare "Romeo ed EnricaInvernizzi", Via F. Sforza 35, 20122, Milan, Italy. alessio.zippo@unitn.it.(10)Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale MaggiorePoliclinico, Milan, 20122, Italy. alessio.zippo@unitn.it.Breast cancer consists of highly heterogeneous tumors, whose cell of origin anddriver oncogenes are difficult to be uniquely defined. Here we report that MYCacts as tumor reprogramming factor in mammary epithelial cells by inducing analternative epigenetic program, which triggers loss of cell identity andactivation of oncogenic pathways. Overexpression of MYC induces transcriptionalrepression of lineage-specifying transcription factors, causing decommissioningof luminal-specific enhancers. MYC-driven dedifferentiation supports the onset ofa stem cell-like state by inducing the activation of de novo enhancers, whichdrive the transcriptional activation of oncogenic pathways. Furthermore, wedemonstrate that the MYC-driven epigenetic reprogramming favors the formation andmaintenance of tumor-initiating cells endowed with metastatic capacity. Thisstudy supports the notion that MYC-driven tumor initiation relies on cellreprogramming, which is mediated by the activation of MYC-dependent oncogenicenhancers, thus establishing a therapeutic rational for treating basal-likebreast cancers.DOI: 10.1038/s41467-018-03264-2 PMCID: PMC5844884PMID: 29523784  [Indexed for MEDLINE]